SecBot SecBot
PRESS-RELEASE ·Filed Nov 16, 2026

NGEN

NervGen Pharma Corp.
NEUTRAL
Impact 4/10
Processed16h 45m ago Wirepress-3403377
Press release · Earnings

Price Chart

Loading chart...

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3403377

Track record

19 reports on NGEN

Performance horizon

7 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +51.65% at T+60 after the May 18, 2026 report. 10 of 10 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Neutral 4/10 Entry price pending
  2. Nov 16, 2026today Press Release Neutral 4/10 Viewing Entry $1.87 Now $1.82 −2.67% settles Nov 23
  3. Nov 12, 20264d ago Press Release Bullish 6/10 Entry $1.63 Now $1.82 +11.66% settles Nov 19
  4. Sep 25, 20267w ago 6-K Bearish 7/10 Entry $1.88 to $1.81 Now $1.82 +3.19% ▲ +3.72% +4.93% vs SPY
  5. Sep 25, 20267w ago Press Release Neutral 4/10 Entry $1.88 to $1.81 Now $1.82 −3.19% ▼ −3.72% −4.93% vs SPY
  6. Sep 24, 20267w ago 6-K Neutral 3/10 Entry $2.02 to $1.76 Now $1.82 −9.90% ▼ −12.87% −12.46% vs SPY
  7. Aug 13, 202613w ago 6-K Neutral 5/10 Entry $1.76 to $1.76 Now $1.82 +3.41% · 0.00% +1.96% vs SPY
  8. Aug 13, 202613w ago Press Release Neutral 5/10 Entry $1.76 to $1.76 Now $1.82 +3.41% · 0.00% +1.96% vs SPY
  9. Jul 2, 202619w ago 6-K Bearish 5/10 Entry $2.12 to $1.86 Now $1.82 +14.15% ▲ +12.26% +13.19% vs SPY
  10. Jun 1, 202624w ago 6-K Bearish 6/10 Entry $2.00 to $1.81 Now $1.82 +9.00% ▲ +9.50% +6.54% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens in 9h 29m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 16, 2026

Fresh NGEN Intelligence

Analysis is for subscribers only.

Subscribe for Full Access